Alvotech Reports Financial Results for First Nine Months of 2023 and Provides a Business Update
Product revenue for the nine months of 2023 increased to $29.8 million, compared to $11.1 million for the same period in 2022 Marketing authorization was received for AVT04 in Canada and Japan, the first for a biosimilar to Stelara® (ustekinumab) The …